Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock

$6.55

2.82% yesterday

Nasdaq, Jun 27, 10:15 pm CET

ISIN

CA60255C1095

Symbol

MNMD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock price

$6.55

+1.33 25.55% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.19 2.82%

ISIN

CA60255C1095

Symbol

MNMD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$494.9m

Enterprise Value

$304.5m

Net debt

$-190.4m

Cash

$212.4m

Shares outstanding

75.5m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

2.22

Financial Health

Equity Ratio

79.91%

Return on Equity

-45.01%

ROCE

-45.47%

ROIC

Debt/Equity

0.10

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-110.8m | $-124.5m

EBIT

$-111.3m

Net Income

$-77.6m | $-113.8m

Free Cash Flow

$-92.0m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

-20.06% | -20.42%

EBIT

-16.93%

Net Income

38.05% | -4.68%

Free Cash Flow

-35.96%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-0.91

FCF per Share

$-1.22

Short interest

14.76%

Employees

74.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Mind Medicine Inc - Ordinary Shares (Sub Voting) forecast:

15x Buy

94%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Mind Medicine Inc - Ordinary Shares (Sub Voting) forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Mind Medicine Inc - Ordinary Shares (Sub Voting)

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	31 31	21% 21% -
- Research and Development Expense	82 82	56% 56% -
EBITDA	-111 -111	20% 20% -
- Depreciation and Amortization	0.50 0.50	83% 83% -
EBIT (Operating Income) EBIT	-111 -111	17% 17% -
Net Profit	-78 -78	38% 38% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock News

Positive

Proactive Investors

●

10 days ago

FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks

The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration. Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, ...

Neutral

Business Wire

●

19 days ago

MindMed Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 128,750 common shares of the Compan...

Positive

The Motley Fool

●

24 days ago

Why Mind Medicine Gave Investors a Powerful Buzz in May

Mind Medicine (MNMD 2.81%), a healthcare company that's looking to develop treatments based on psychedelic compounds, was something of a sleeper stock in May. Several positive developments pushed the highly specialized enterprise's share price higher, to the point where it closed the month up almost 14% in price.

More Mind Medicine Inc - Ordinary Shares (Sub Voting) News

Company Profile

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Head office	Canada
CEO	Robert Barrow
Employees	74
Founded	2019
Website	mindmed.co

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now